We provide our forecast for its SCB-2019 and SCB-313. The company's valuation is largely anchored on the sales of its COVID-19 vaccine thought SCB-313 is interesting with a large addressable market.
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.